An olfactory 'stress test' may detect preclinical Alzheimer's disease

BMC Neurology

Volumn 12, Issue , 2012, Pages

  Schofield, Peter W ^a   Ebrahimi, Houman ^b   Jones, Alison L ^c   Bateman, Grant A ^b   Murray, Sonya R ^d  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b JOHN HUNTER HOSPITAL   (Australia)

^c UNIVERSITY OF WOLLONGONG   (Australia)

^d Neuropsychiatry Service   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; ATROPINE; DIAGNOSTIC AGENT;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN SIZE; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; EPISODIC MEMORY; FEMALE; GENOTYPE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OLFACTORY DISCRIMINATION; DRUG EFFECT; EARLY DIAGNOSIS; INTRANASAL DRUG ADMINISTRATION; ODOR; OLFACTORY BULB; PATHOPHYSIOLOGY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

ADMINISTRATION, INTRANASAL; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ATROPINE; EARLY DIAGNOSIS; FEMALE; HUMANS; MALE; OLFACTORY BULB; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SMELL;

EID: 84860345489     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-12-24     Document Type: Article

References (43)

1. Price JL, McKeel DW, Buckles VD, Roe CM, Xiong C, Grundman M, Hansen LA, Petersen RC, Parisi JE, Dickson DW, Smith CD, Davis DG, Schmitt FA, Markesbery WR, Kaye J, Kurlan R, Hulette C, Kurland BF, Higdon R, Kukull W, Morris JC. Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer's disease. Neurobiol Aging 2009, 30:1026-1036. 10.1016/j.neurobiolaging.2009.04.002, 2737680, 19376612.
2. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991, 82:239-259. 10.1007/BF00308809, 1759558.
3. Kovacs T, Cairns NJ, Lantos PL. β-Amyloid deposition and neurofibrillary tangle formation in the olfactory bulb in ageing and Alzheimer's disease. Neuropathol Appl Neurobiol 1999, 25:481-491. 10.1046/j.1365-2990.1999.00208.x, 10632898.
4. Hawkes CH, Doty RL. The neurology of olfaction 2009, Cambridge Univ. Press, Cambridge, UK.
5. Wilson RS, Schneider JA, Arnold SE, Tang Y, Boyle PA, Bennett DA. Olfactory identification and incidence of mild cognitive impairment in older age. Arch Gen Psychiatry 2007, 64:802-808. 10.1001/archpsyc.64.7.802, 17606814.
6. Graves AB, Bowen JD, Rajaram L, McCormick WC, McCurry SM, Schellenberg GD, Larson EB. Impaired olfaction as a marker for cognitive decline: interaction with apolipoprotein E epsilon4 status. Neurology 1999, 53:1480-1487. 10.1212/WNL.53.7.1480, 10534255.
7. Devanand DP, Tabert MH, Cuasay K, Manly JJ, Schupf N, Brickman AM, Andrews H, Brown TR, DeCarli C, Mayeux R. Olfactory identification deficits and MCI in a multi-ethnic elderly community sample. Neurobiol Aging 2010, 31:1593-1600. 10.1016/j.neurobiolaging.2008.09.008, 2947189, 18963256.
8. Doležal V, Kašparová J. ß-Amyloid and cholinergic neurons. Neurochem Res 2003, 28:499-506. 10.1023/A:1022865121743, 12675138.
9. Wesson DW, Levy E, Nixon RA, Wilson DA. Olfactory dysfunction correlates with amyloid-beta burden in an Alzheimer's disease mouse model. J Neurosci 2010, 30:505-14. 10.1523/JNEUROSCI.4622-09.2010, 2826174, 20071513.
10. Castillo PE, Carleton A, Vincent JD, Lledo PM. Multiple and opposing roles of cholinergic transmission in the main olfactory bulb. J Neurosci 1999, 19:9180-9191.
11. Chaudhury D, Escanilla O, Linster C. Bulbar acetylcholine enhances neural and perceptual odor discrimination. J Neurosci 2009, 29:52-60. 10.1523/JNEUROSCI.4036-08.2009, 2768367, 19129384.
12. Velayudhan L, Lovestone S. Smell identification test as a treatment response marker in patients with Alzheimer disease receiving donepezil. J Clin Psychopharmacol 2009, 29:387-90. 10.1097/JCP.0b013e3181aba5a5, 19593181.
13. Sunderland T, Tariot PN, Cohen RM, Weingartner H, Mueller EA, Murphy DL. Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. A dose-response study. Arch Gen Psychiatry 1987, 44:418-26. 10.1001/archpsyc.1987.01800170032006, 3579494.
14. Graff CL, Zhao R, Pollack GM. Pharmacokinetics of substrate uptake and distribution in Murine brain after nasal instillation. Pharm Res 2005, 22:235-44. 10.1007/s11095-004-1191-5, 15783071.
15. Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci. 2000, 11:1-18. 10.1016/S0928-0987(00)00087-7, 10913748.
16. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatry Res 1975, 12:189-198.
17. Schofield PW, Lee SJ, Lewin TJ, Lyall G, Moyle J, Attia J, McEvoy M. The Audio Recorded Cognitive Screen (ARCS): a flexible hybrid cognitive test instrument. J Neurol Neurosurg Psychiatry 2010, 81:602-607. 10.1136/jnnp.2009.188003, 19965841.
18. Lechner-Scott J, Kerr T, Spencer B, Agland S, Lydon A, Schofield PW. The Audio Recorded Cognitive Screen (ARCS) in patients with multiple sclerosis: a practical tool for multiple sclerosis clinics. Mult Scler 2010, 16:1126-1133. 10.1177/1352458510374743, 20621944.
19. Loughland CM, Allen J, Gianacas L, Schofield PW, Lewin TJ, Hunter M, Carr VJ. Brief neuropsychological profiles in psychosis: a pilot study using the Audio Recorded Cognitive Screen (ARCS). Acta Neuropsychiatrica 2010, 22:243-252.
20. American Psychiatric Association Diagnostic and statistical manual of mental disorders 1994, American Psychiatric Press, Washington DC, 4, American Psychiatric Association.
21. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work groups under the auspices of department of health and human services task force on alzheimer's disease. Neurology 1984, 34:939-944. 10.1212/WNL.34.7.939, 6610841.
22. Doty RL, Shaman P, Dann M. Development of the University of Pennsylvania Smell Identification Test: a standardized microencapsulated test of olfactory function. Physiol Behav 1984, 32:489-502. 10.1016/0031-9384(84)90269-5, 6463130.
23. Doty RL, Frye RE, Agrawal U. Internal consistency reliability of the fractionated and whole University of Pennsylvania Smell Identification Test. Percept Psychophys 1989, 45:381-384. 10.3758/BF03210709, 2726398.
24. Jack CR, Twomey CK, Zinsmeister AR, Sharbrough FW, Petersen RC, Cascino GD. Anterior temporal lobes and hippocampal formations: normative volumetric measurements from MR images in young adults. Radiology 1989, 172:549-554.
25. Tae WS, Kim SS, Lee KU, Nam EC, Kim KW. Validation of hippocampal volumes measured using a manual method and two automated methods (FreeSurfer and IBASPM) in chronic major depressive disorder. Neuroradiology 2008, 50:569-581. 10.1007/s00234-008-0383-9, 18414838.
26. Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, van der Kouwe A, Killiany R, Kennedy D, Klaveness S, Montillo A, Makris N, Rosen B, Dale AM. Whole brain segmentation: automated labelling of neuroanatomical structures in the human brain. Neuron 2002, 33:341-355. 10.1016/S0896-6273(02)00569-X, 11832223.
27. Buckner RL, Head D, Parker J, Fotenos AF, Marcus D, Morris JC, Snyder AZ. A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume. Neuroimage 2004, 23:724-738. 10.1016/j.neuroimage.2004.06.018, 15488422.
28. Olofsson JK, Rönnlund M, Nordin S, Nyberg L, Nilsson L-G, Larson M. Odor identification deficit as a predictor of five-year global cognitive change: interactive effects with age and ApoE-ε{lunate}4. Behav Genet 2009, 39:496-503. 10.1007/s10519-009-9289-5, 19633944.
29. Schubert CR, Carmichael LL, Murphy C, Klein BEK, Klein R, Cruikshanks KJ. Olfaction and the 5-yr incidence of cognitive impairment in an epidemiological study of older adults. J Am Geriatr Soc 2008, 56:1517-1521. 10.1111/j.1532-5415.2008.01826.x, 2587240, 18662205.
30. Mortimer J, Gosche K, Riley K, Markesbery WR, Snowdon DA. Delayed recall, hippocampal volume and Alzheimer neuropathology. Neurology 2004, 62:428-432. 10.1212/01.WNL.0000106463.66966.65, 14872025.
31. Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, Miller BL, Koeppe RA, Mathis CA, Weiner MW, Jagust WJ. Alzheimer's disease neuroimaging Initiative: episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 2009, 132:1310-1323. 10.1093/brain/awn320, 2677792, 19042931.
32. Corder E, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein e type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261:921-923. 10.1126/science.8346443, 8346443.
33. Kok E, Haikonen S, Luoto T, Huhtala H, Goebeler S, Haapasalo H, Karhunen PJ. Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age. Ann Neurol 2009, 65:650-657. 10.1002/ana.21696, 19557866.
34. Mesulam MM, Geula C. Nucleus basalis (Ch4) and cortical cholinergic innervation in the human brain: observations based on the distribution of acetylcholinesterase and choline acetyltransferase. J Comp Neurol 1988, 275:216-240. 10.1002/cne.902750205, 3220975.
35. Mesulam M. The cholinergic lesion of Alzheimer's disease: pivotal factor or side show?. Learn Mem 2004, 11:43-49. 10.1101/lm.69204, 14747516.
36. Yan Z, Feng J. Alzheimer's disease: interactions between cholinergic functions and Beta- amyloid. Curr Alzheimer Res 2004, 1:241-48. 10.2174/1567205043331992, 15975053.
37. Lehéricy S, Hirsch EC, Cervera-Piérot P, Hersh LB, Bakchine S, Piette F, Duyckaerts C, Hauw JJ, Javoy-Agid F, Agid Y. Heterogeneity and selectivity of degeneration of cholinergic neurons in the basal forebrain of patients with Alzheimer's disease. J Comp Neurol 1993, 330:15-31. 10.1002/cne.903300103, 8468401.
38. Bales KR, Tzavara ET, Wu S, Wade MR, Bymaster FP, Paul SM, Nomikos GG. Cholinergic dysfunction in a mouse model of Alzheimer's disease is reversed by an anti-ABeta antibody. J Clin Invest 2006, 116:825-832. 10.1172/JCI27120, 1378188, 16498501.
39. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH. Natural oligomers of amyloid Beta protein specifically disrupt cognitive function. Nature Neurosci 2005, 8:79-84. 10.1038/nn1372, 15608634.
40. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J. Soluble amyloid Beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 1999, 155:853-862. 10.1016/S0002-9440(10)65184-X, 1866907, 10487842.
41. Teller JK, Russo C, DeBusk LM, Angelini G, Zaccheo D, Dagna-Bricarelli F, Scartezzini P, Bertolini S, Mann DM, Tabaton M, Gambetti P. Presence of soluble amyloid Beta-peptide precedes amyloid plaque formation in down's syndrome. Nature Med 1996, 2:93-95. 10.1038/nm0196-93, 8564851.
42. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL. Soluble pool of a beta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 1999, 46:860-866. 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M, 10589538.
43. Wolf H, Hensel A, Kruggel F, Riedel-Heller SG, Arendt T, Wahlund L-O, Gertz H-J. Structural correlates of mild cognitive impairment. Neurobiol Aging 2004, 25:913-924. 10.1016/j.neurobiolaging.2003.08.006, 15212845.